Bavencio (Avelumab), Inlyta (Axitinib) Combination Approved for Advanced Renal Cell Carcinoma by FDA

Approval marks the first anti-PD-L1 therapy combination for RCC.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news

Related Links:

.
Source: Expert Opinion on Biological Therapy - Category: Drugs & Pharmacology Authors: Source Type: research
Publication date: Available online 12 October 2019Source: European UrologyAuthor(s): Karlijn de Joode, Astrid A.M. van der Veldt
Source: European Urology - Category: Urology & Nephrology Source Type: research
In conclusion, miR-877 may play an antitumor role in cervical cancer by directly targeting MACC1, which suggests that this miRNA may be a promising therapeutic target for the treatment of patients with such an aggressive gynecological cancer. PMID: 31602243 [PubMed]
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
This study included 37 TFEB-altered tumors: 15 6p21.1-amplified and 22 TFEB-rearranged (including 5 cases from The Cancer Genome Atlas data set). TFEB status was verified using a combination of fluorescent in situ hybridization (n=27) or comprehensive molecular profiling (n=13) and digital droplet polymerase chain reaction was used to quantify TFEB mRNA expression in 6p21.1-amplified (n=9) and TFEB-rearranged renal tumors (n=19). These results were correlated with TFEB immunohistochemistry. TFEB-altered tumors had higher TFEB expression when normalized to B2M (mean: 168.9%, n=28), compared with non–TFEB-altered contr...
Source: The American Journal of Surgical Pathology - Category: Pathology Tags: Original Articles Source Type: research
This study aimed to evaluate the utility of the AACI for predicting long-term survival in patients with surgically treated non-metastatic clear cell RCC (ccRCC).MethodsData from 698 patients with non-metastatic ccRCC who underwent radical or partial nephrectomy as primary therapy from a multi-institutional Korean collaboration between 1988 and 2015 were retrospectively analyzed. Clinicopathological variables and survival outcomes of those with AACI scores  ≤ 3 (n = 324), 4–5 (n = 292), and ≥ 6 (n = 82) were compared.ResultsPatients with a hig...
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
We present a 66 year-old-man that was referred to our center after the casual finding of a renal mass. With a suspected diagnosis of a renal cell carcinoma, a partial nephrectomy was performed. The histological study revealed the final diagnosis of a benign renal schwannoma.
Source: Urology Case Reports - Category: Urology & Nephrology Source Type: research
AbstractNivolumab is an anti-programmed cell death-1 antibody that is utilized as an immune checkpoint inhibitor for several malignancies. However, this agent is associated with immune-related adverse events (irAEs), mainly in the spectrum of autoimmune disease including interstitial pneumonia, colitis, type 1 diabetes, and renal impairment. We herein present the case of a 59-year-old man with renal cell carcinoma who developed worsening renal function approximately 4  months after initiation of nivolumab. Urinalysis showed proteinuria and microscopic hematuria along with increase levels ofN-acetyl- β-d-glucosami...
Source: CEN Case Reports - Category: Urology & Nephrology Source Type: research
AbstractPurpose of ReviewTo critically review the potential clinical applications of prostate-specific membrane antigen (PSMA) radioactive ligands in renal cell carcinoma (RCC).Recent FindingsRadioactive probes targeting PSMA hold promise in several malignancies in addition to prostate cancer, owing to the expression of PSMA by tumor neovasculature. The majority of clear cell RCCs (ccRCC), the most malignant RCC subtype, express PSMA on tumor-associated neovasculature. The endothelium of less aggressive RCC subtypes is PSMA positive in a lower, but still significant percentage of cases. PSMA might therefore represent an in...
Source: Current Urology Reports - Category: Urology & Nephrology Source Type: research
We report a case of CRCC with sarcomatoid differentiation in a woman in her sixties which was revealed by acute pyelonephritis and had a lethal outcome.
Source: Urology Case Reports - Category: Urology & Nephrology Source Type: research
Publication date: October 2019Source: European Urology Supplements, Volume 18, Issue 9Author(s): P. Romagnani, F. Di Maida, A. Mari, G. Novara, A. Antonelli, R. Bertolo, G. Bianchi, C. Fiori, M. Furlan, N. Longo, V. Mirone, R. Tellini, F. Porpiglia, R. Schiavina, S. Scelzi, R. Campi, C. Simeone, C. Terrone, M. Carini, A. Minervini
Source: European Urology Supplements - Category: Urology & Nephrology Source Type: research
More News: Cancer & Oncology | Carcinoma | Kidney Cancer | Renal Cell Carcinoma